Immuno-oncology drug developer Oxis International has agreed to buy Georgetown Translational Pharmaceuticals (GTP) in exchange of 33% of its outstanding shares.

The acquisition will add a class of close-to-market central nervous systems (CNS) products to Oxis, and accelerate the clinical development of cancer and neurologic disease-related treatments.

The merger also includes a $125m upfront payment from Allergan, a company owned by the newly appointed CEO of Oxis. Allergan will also provide potential regulatory and commercial milestones of up to $875m.

“The acquirer plans to raise $26.3m through a private placement of shares to partly fund the acquisition.”

Hangzhou Tianmushan Pharmaceutical intends to acquire an AnhuiIn-based pharmaceutical company in a $52.7m deal.

The acquirer plans to raise $26.3m through a private placement of shares to partly fund the acquisition.

Biopharmaceutical company Sinovac Biotech will be bought by Shandong Sinobioway Biomedicine for a cash consideration of $8 a share.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

In a $2m deal, Zhejiang Jingxin Pharmaceutical will purchase an up to 25% stake in Spes Pharmaceuticals.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now